The MTBP has been developed under the umbrella of the Cancer Core Europe, which is formed by seven leading European
oncology centers with the aim of implementing new therapeutic strategies involving knowledge, data and technology sharing.
Variants are classified by their
functional and predictive relevance following
international guidelines as available or developing
in-house expert consensus otherwise.
The public version of the portal does not incorporate information that cannot be retrieved from a generic input
(such as the germline and/or tumor origin of the variants or their allele frequency)
or implement features dependant on project specifications (such as match variants with clinical trials of interest).
Instead, the public MTBP provides an analytical framework to analyse cancer variants that supports (but
does not substitute)
the healthcare professional judgement.